EVIDENCE PROFILE / PUBLISHED
GHK-Cu
A copper(II) complex of the tripeptide glycyl-histidyl-lysine, supported mainly by cell and animal tissue-remodelling work and a very small topical human literature.
Evidence at a glance
- Human
- LimitedOne very small randomized study of a topical skin-care regimen.
- Animal/cell
- Not rated
- Approved medicine
- Not rated
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“Copper tripeptide in a finished cream, a cell-culture reagent, and an injectable bulk substance are three different evidence questions.”
GHK-Cu has a plausible tissue-remodelling story and decades of laboratory work. The clinical record is much thinner, and evidence for a cosmetic cream cannot be transferred to an injectable material.
Identity and established aliases
GHK is the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma. It binds copper(II) to form GHK-Cu. Cosmetic ingredient lists may use copper tripeptide-1, but naming alone does not establish concentration, chemical state, delivery, purity, or equivalence to a research vial.
Why researchers study it
GHK-Cu has been investigated as a modulator of extracellular-matrix production and turnover. Cultured fibroblast work reported increased collagen production, while rat wound-chamber work reported increased extracellular-matrix accumulation. These findings suggest pathways worth studying in tissue repair; they do not establish a clinical outcome.
Approved medicines and investigational uses
No GHK-Cu active-ingredient record was returned by Health Canada's Drug Product Database under the reviewed name. The reviewed FDA material does not identify an FDA-approved injectable GHK-Cu drug. FDA places injectable GHK-Cu among substances with limited human safety data and potential immunogenicity concerns; non-injectable compounding status is a separate, still-evolving regulatory question.
Human research has primarily examined topical multi-ingredient skin-care regimens or wound-related contexts. A cosmetic ingredient's lawful use and a drug approval are not the same regulatory category.
What human studies show
In a randomized study after carbon-dioxide laser resurfacing, 13 participants completed topical regimens with or without GHK-Cu-containing products. Blinded and computer assessments found no significant difference in erythema, wrinkles, or overall skin quality; a questionnaire favoured the GHK-Cu regimen for patient satisfaction. The sample was tiny and the intervention was a skin-care regimen, not isolated injected GHK-Cu.
That result does not establish wound treatment, anti-aging, hair growth, systemic effects, or safety by other routes. FDA describes human safety information for injectable GHK-Cu as limited.
What cells and animal studies show
Cultured human fibroblasts produced more collagen under specific GHK-Cu conditions. In rat wound chambers, investigators reported increased extracellular-matrix accumulation. These controlled models support a tissue-remodelling hypothesis, but model exposure and endpoints differ from a finished human product and from patient-centred outcomes.
Popular claims and evidence limits
Popular claims include reducing wrinkles, reversing skin aging, growing hair, accelerating wounds, and producing broad anti-inflammatory or regenerative effects. The reviewed human evidence is insufficient for those broad statements. Positive cell markers and consumer satisfaction after a combined skin regimen are not proof of clinical regeneration.
What remains uncertain
Larger independent human trials, standardized formulations, route-specific absorption, clinically meaningful endpoints, and long-term safety remain gaps. Injectable use raises additional questions about aggregation, impurities, immunogenicity, sterility, endotoxin, and copper exposure that topical studies do not answer.
